LOGIN  |  REGISTER
Astria Therapeutics

Sera Prognostics (NASDAQ: SERA) Stock Quote

Last Trade: US$8.87 -0.59 -6.24
Volume: 97,851
5-Day Change: -1.66%
YTD Change: 48.33%
Market Cap: US$279.050M

Latest News From Sera Prognostics

SALT LAKE CITY , March 20, 2024 /PRNewswire/ -- Sera Prognostics Inc., The Pregnancy Company® (Nasdaq: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, today announced financial results for the fourth quarter and full year ended December 31, 2023 . Recent Highlights: Announced that the Data Safety Monitoring Board (DSMB) overseeing... Read More
SALT LAKE CITY , March 4, 2024 /PRNewswire/ -- Sera Prognostics Inc., The Pregnancy Company® (NASDAQ: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, today announced that it will report fourth quarter and full year 2023 financial results on Wednesday, March 20 , after the close of the market. The Company will host a corresponding... Read More
SALT LAKE CITY , Feb. 29, 2024 /PRNewswire/ -- Sera Prognostics Inc., The Pregnancy Company ® (NASDAQ: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, today announced that the company will present at the TD Cowen 44 th Annual Healthcare Conference on Monday, March 4, 2024 at 2:50 p.m. ET . Zhenya Lindgardt, President and CEO, will... Read More
SALT LAKE CITY , Dec. 6, 2023 /PRNewswire/ -- Sera Prognostics Inc. , The Pregnancy Company ® (Nasdaq: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, today announced that the Data Safety Monitoring Board (DSMB) overseeing its pivotal P rematurity R isk Assessment Combined with Clinical I nterventions for Improved Neonatal Outco ME s... Read More
SALT LAKE CITY , Nov. 22, 2023 /PRNewswire/ -- Sera Prognostics Inc. , The Pregnancy Company ® (Nasdaq: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, today announced that the company will present at the upcoming 35 th Annual Piper Sandler Healthcare Conference to be held November 28-30, 2023 in New York City . Doug Fisher , Sera's... Read More
SALT LAKE CITY , Nov. 8, 2023 /PRNewswire/ -- Sera Prognostics Inc., The Pregnancy Company® (Nasdaq: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, today announced financial results for the third quarter of 2023 ended September 30, 2023 . Recent Highlights: Sera Board of Directors approved permanent President and CEO and CFO... Read More
SALT LAKE CITY , Oct. 25, 2023 /PRNewswire/ -- Sera Prognostics Inc., The Pregnancy Company® (NASDAQ: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, today announced that it will report third quarter fiscal year 2023 financial results on Wednesday, November 8, 2023 , after the close of the market. The Company will host a corresponding... Read More
SALT LAKE CITY , Sept. 21, 2023 /PRNewswire/ -- Sera Prognostics Inc., The Pregnancy Company ® (Nasdaq: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, today announced that the company will present at the upcoming Cantor Fitzgerald Global Healthcare Conference 2023 to be held September 26-28, 2023 in New York City . Zhenya Lindgardt,... Read More
HealthStocksHub
SALT LAKE CITY , Aug. 9, 2023 /PRNewswire/ -- Sera Prognostics Inc., The Pregnancy Company® (Nasdaq: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, today announced financial results for the second quarter of 2023 ended June 30, 2023.... Read More
SALT LAKE CITY , July 31, 2023 /PRNewswire/ -- Sera Prognostics Inc., The Pregnancy Company ® (NASDAQ: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, today announced that it will report second quarter fiscal year 2023 financial results on Wednesday, August 9, 2023 , after the close of the market. The Company will host a corresponding... Read More
Aligning Management Team given New Refined Commercial Focus on Institutions Starting with Recent Appointment of Board Member Zhenya Lindgardt as Interim President and CEO Engages Leading Strategy House to Evaluate Best Pathways Toward Targeting Enhanced Revenue Generation at Significantly Reduced Operating Costs Nadia Altomare Expected to Move from Chief Commercial Officer to Consulting Role to Support Driving Efficiency and... Read More
SALT LAKE CITY , May 15, 2023 /PRNewswire/ -- Sera Prognostics Inc. , The Pregnancy Company ® (NASDAQ: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, today announced the retirement of the Company's President and CEO, Gregory C. Critchfield , M.D., M.S. Dr. Critchfield is retiring after 12 years of dedicated and valuable service to the... Read More
SALT LAKE CITY , May 10, 2023 /PRNewswire/ -- Sera Prognostics Inc., The Pregnancy Company ® (Nasdaq: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, today announced financial results for the first quarter of 2023 ended March 31, 2023 . Recent Highlights: Announced positive top-line results from the AVERT PRETERM TRIAL ( Serum... Read More
SALT LAKE CITY , April 27, 2023 /PRNewswire/ -- Sera Prognostics Inc., The Pregnancy Company ® (NASDAQ: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, today announced that it will report first quarter fiscal year 2023 financial results on Wednesday, May 10, 2023 , after the close of the market. The Company will host a corresponding... Read More
SALT LAKE CITY , March 22, 2023 /PRNewswire/ -- Sera Prognostics Inc. , The Pregnancy Company® (Nasdaq: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, today announced financial results for the fourth quarter and full year 2022 ended December 31, 2022 . Recent Highlights: Announced positive top-line results from the AVERT PRETERM TRIAL... Read More
SALT LAKE CITY , March 9, 2023 /PRNewswire/ -- Sera Prognostics Inc., The Pregnancy Company ® (NASDAQ: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, today announced that it will report fourth quarter and full year 2022 financial results on Wednesday, March 22, 2023 , after the close of the market. The Company will host a corresponding... Read More
SALT LAKE CITY , Feb. 23, 2023 /PRNewswire/ -- Sera Prognostics Inc. , The Pregnancy Company ® (NASDAQ: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, today announced that the company will present at the upcoming Cowen Health Care Conference March 6-8, 2023 in Boston and the Oppenheimer 33rd Annual Healthcare Conference held to be held... Read More
PreTRM® test-and-treat strategy demonstrates statistically and clinically significant improvement in neonatal health outcomes and hospital length-of-stay SALT LAKE CITY , Feb. 15, 2023 /PRNewswire/ -- Sera Prognostics Inc., The Pregnancy Company® (NASDAQ: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, today announced top-line results... Read More
Sera's PreTRM® test-and-treat strategy helps build on Fors Marsh's commitment to investing in its employees to enable a healthy and viable workforce SALT LAKE CITY and ARLINGTON, Va. , Nov. 29, 2022 /PRNewswire/ -- Sera Prognostics Inc. , The Pregnancy Company® (NASDAQ: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, and Fors Marsh , a... Read More

COPYRIGHT ©2023 HEALTH STOCKS HUB